Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients.

The monitoring of changes in the protein composition of the cerebrospinal fluid (CSF) can be used as a sensitive indicator of central nervous system (CNS) pathology, yet its systematic application to analysis of CNS neoplasia has been limited. There is a pressing need for both a better understanding of gliomagenesis and the development of reliable biomarkers of the disease. In this report, we used two proteomic techniques, two-dimensional gel electrophoresis (2-DE), and cleavable Isotope-Coded Affinity Tag (cICAT) to compare CSF proteomes to identify tumor- and grade-specific biomarkers in patients bearing brain tumors of differing histologies and grades. Retrospective analyses were performed on 60 samples derived from astrocytomas WHO grade II, III, and IV, schwannomas, metastastic brain tumors, inflammatory samples, and non-neoplastic controls. We identified 103 potential tumor-specific markers of which 20 were high-grade astrocytoma-specific. These investigations allowed us to identify a spectrum of signature proteins that could be used to distinguish CSF derived from control patients versus those with low- (AII) or high-grade (AIV) astrocytoma. These proteins may represent new diagnostic, prognostic, and disease follow-up markers when used alone or in combination. These candidate biomarkers may also have functional properties that play a critical role in the development and malignant progression of human astrocytomas, thus possibly representing novel therapeutic targets for this highly lethal disease.

[1]  Erwin G. Van Meir,et al.  Attractin Is Elevated in the Cerebrospinal Fluid of Patients with Malignant Astrocytoma and Mediates Glioma Cell Migration , 2006, Clinical Cancer Research.

[2]  F. Niyonsaba,et al.  Protective roles of the skin against infection: implication of naturally occurring human antimicrobial agents beta-defensins, cathelicidin LL-37 and lysozyme. , 2005, Journal of dermatological science.

[3]  Erwin G. Van Meir,et al.  Cytokine Expression and Signaling in Brain Tumors , 2005 .

[4]  C. Bessant,et al.  i-Tracker: For quantitative proteomics using iTRAQ™ , 2005, BMC Genomics.

[5]  G. Omenn,et al.  Exploring the Human Plasma Proteome , 2005, Proteomics.

[6]  M. Sjögren,et al.  The Use of Proteomics in Biomarker Discovery in Neurodegenerative Diseases , 2005, Disease markers.

[7]  E. Petricoin,et al.  Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Recht,et al.  High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. , 2005, Cancer research.

[9]  M. West,et al.  Gene expression profiling and genetic markers in glioblastoma survival. , 2005, Cancer research.

[10]  L. Chung,et al.  Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. , 2005, Cancer research.

[11]  S. Demaria,et al.  Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain , 2005, Laboratory Investigation.

[12]  Eric P Hoffman,et al.  Neuronal plasticity after spinal cord injury: identification of a gene cluster driving neurite outgrowth , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  E. Schwinger,et al.  Mutation analysis in the fibroblast growth factor 14 gene: frameshift mutation and polymorphisms in patients with inherited ataxias , 2005, European Journal of Human Genetics.

[14]  B. Neyns,et al.  Neuropathological and molecular aspects of low-grade and high-grade gliomas. , 2004, Acta neurologica Belgica.

[15]  H. Griffiths,et al.  The use of proteomics for the assessment of clinical samples in research. , 2004, Clinical biochemistry.

[16]  Daniel J Brat,et al.  Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma , 2004, Laboratory Investigation.

[17]  A. Nakeff,et al.  SPARC Modulates Cell Growth, Attachment and Migration of U87 Glioma Cells on Brain Extracellular Matrix Proteins , 2001, Journal of Neuro-Oncology.

[18]  M. Koskiniemi,et al.  Malignancy markers in the cerebrospinal fluid , 1988, European Journal of Pediatrics.

[19]  S. Schwab,et al.  The proteome of human brain microdialysate , 2003, Proteome Science.

[20]  M. Ferrari,et al.  Clinical proteomics: Written in blood , 2003, Nature.

[21]  F. Garrido,et al.  MHC class I‐deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components , 2003, International journal of cancer.

[22]  Rob Pieters,et al.  Identification of Tumor‐Related Proteins by Proteomic Analysis of Cerebrospinal Fluid from Patients with Primary Brain Tumors , 2003, Journal of neuropathology and experimental neurology.

[23]  J. Cairncross,et al.  Long‐Term Survivors of Glioblastoma: Statistical Aberration or Important Unrecognized Molecular Subtype? , 2003, Cancer journal.

[24]  N. Lemke,et al.  Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. , 2002, Cancer research.

[25]  J. Duke-Cohan,et al.  Human Secreted Attractin Disrupts Neurite Formation in Differentiating Cortical Neural Cells In Vitro , 2002, Journal of neuropathology and experimental neurology.

[26]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[27]  D. Wozniak,et al.  Ataxia and Paroxysmal Dyskinesia in Mice Lacking Axonally Transported FGF14 , 2002, Neuron.

[28]  Ruedi Aebersold,et al.  Proteome analysis of low-abundance proteins using multidimensional chromatography and isotope-coded affinity tags. , 2002, Journal of proteome research.

[29]  Erwin G. Van Meir,et al.  Genetic and Biologic Progression in Astrocytomas and Their Relation to Angiogenic Dysregulation , 2002, Advances in anatomic pathology.

[30]  C. Rohlff.  Proteomics in neuropsychiatric disorders. , 2001, The international journal of neuropsychopharmacology.

[31]  G. Barsh,et al.  Attractin/mahogany/zitter plays a critical role in myelination of the central nervous system. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G. Fuller,et al.  Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling. , 2000, Histology and histopathology.

[33]  M. L. Phillips,et al.  Astrocytomas: the clinical picture. , 2000, Clinical journal of oncology nursing.

[34]  J. Duke-Cohan,et al.  Attractin: a cub-family protease involved in T cell-monocyte/macrophage interactions. , 2000, Advances in experimental medicine and biology.

[35]  S. Dudas,et al.  Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[37]  G. Freeman,et al.  Attractin (DPPT-L), a member of the CUB family of cell adhesion and guidance proteins, is secreted by activated human T lymphocytes and modulates immune cell interactions. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Erwin G. Van Meir,et al.  Upregulation of Interleukin 8 by Oxygen-deprived Cells in Glioblastoma Suggests a Role in Leukocyte Activation, Chemotaxis, and Angiogenesis , 1997, The Journal of experimental medicine.

[39]  S. Coons,et al.  Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells , 1997, Oncogene.

[40]  C. Morimoto,et al.  Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. , 1996, Journal of immunology.

[41]  Erwin G. Van Meir.  Cytokines and tumors of the central nervous system , 1995, Glia.

[42]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[43]  P. Knopf,et al.  Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. , 1992, Immunology today.

[44]  R. Halaban,et al.  Localization of basic fibroblast growth factor mRNA in melanocytic lesions by in situ hybridization. , 1991, The Journal of investigative dermatology.

[45]  S. Suster,et al.  Induction of different morphologic features of malignant melanoma and pigmented lesions after transformation of murine melanocytes with bFGF-cDNA and H-ras, myc, neu, and E1a oncogenes. , 1991, The American journal of pathology.

[46]  T. Koch,et al.  Detection of central nervous system metastasis with cerebrospinal fluid beta‐2‐microglobulin , 2006, Cancer.

[47]  C R Merril,et al.  Two-dimensional gel electrophoresis of cerebrospinal fluid proteins. , 1980, Clinical chemistry.

[48]  R. Morantz,et al.  Immunohistologic evaluation of the lymphoreticular infiltrate of human central nervous system tumors. , 1979, Journal of the National Cancer Institute.